These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11604249)

  • 1. Stereoselective effect of (R)- and (S)-1-methyl-1,2,3,4-tetrahydroisoquinolines on a mouse model of Parkinson's disease.
    Abe K; Taguchi K; Wasai T; Ren J; Utsunomiya I; Shinohara T; Miyatake T; Sano T
    Brain Res Bull; 2001 Sep; 56(1):55-60. PubMed ID: 11604249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Properties of 3-methyl-TIQ and 3-methyl-N-propargyl-TIQ for preventing MPTP-induced parkinsonism-like symptoms in mice.
    Saitoh K; Abe K; Chiba T; Katagiri N; Saitoh T; Horiguchi Y; Nojima H; Taguchi K
    Pharmacol Rep; 2013; 65(5):1204-12. PubMed ID: 24399716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of neurotoxicity of TIQ and MPTP and of parkinsonism-preventing effect of 1-MeTIQ by in vivo measurement of pre-synaptic dopamine transporters and post-synaptic dopamine D(2) receptors in the mouse striatum.
    Ishiwata K; Koyanagi Y; Abe K; Kawamura K; Taguchi K; Saitoh T; Toda J; Senda M; Sano T
    J Neurochem; 2001 Nov; 79(4):868-76. PubMed ID: 11723179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse.
    Abe K; Taguchi K; Wasai T; Ren J; Utsunomiya I; Shinohara T; Miyatake T; Sano T
    Brain Res; 2001 Jul; 907(1-2):134-8. PubMed ID: 11430895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventative effects of 1-methyl-1,2,3,4-tetrahydroisoquinoline derivatives (
    Munakata H; Ishikawa R; Saitoh T; Kambe T; Chiba T; Taguchi K; Abe K
    Can J Physiol Pharmacol; 2022 Jul; 100(7):594-611. PubMed ID: 35413210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 1,2,3,4-tetrahydroisoquinoline derivatives on dopaminergic spontaneous discharge in substantia nigra neurons in rats.
    Chiba H; Sato H; Abe K; Saito T; Horiguchi Y; Nojima H; Taguchi K
    Pharmacology; 2015; 95(1-2):87-94. PubMed ID: 25633935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventative effects of 1,3-dimethyl- and 1,3-dimethyl-N-propargyl-1,2,3,4-tetrahydroisoquinoline on MPTP-induced Parkinson's disease-like symptoms in mice.
    Katagiri N; Chida S; Abe K; Nojima H; Kitabatake M; Hoshi K; Horiguchi Y; Taguchi K
    Brain Res; 2010 Mar; 1321():133-42. PubMed ID: 20114039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of 1,2,3,4,-tetrahydroisoquinoline administration under conditions of CYP2D inhibition on dopamine metabolism, level of tyrosine hydroxylase protein and the binding of [3H]GBR 12,935 to dopamine transporter in the rat nigrostriatal, dopaminergic system.
    Lorenc-Koci E; Antkiewicz-Michaluk L; Wardas J; Zapała M; Wierońska J
    Brain Res; 2004 May; 1009(1-2):67-81. PubMed ID: 15120584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of 1-methyl 1,2,3,4-tetrahydroisoquinoline level in substantia nigra of the aged rat.
    Ayala A; Parrado J; Cano J; Machado A
    Brain Res; 1994 Feb; 638(1-2):334-6. PubMed ID: 8199872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease.
    Teismann P; Ferger B
    Synapse; 2001 Feb; 39(2):167-74. PubMed ID: 11180504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
    Araki T; Muramatsu Y; Tanaka K; Matsubara M; Imai Y
    Neurosci Lett; 2001 Oct; 312(1):50-4. PubMed ID: 11578843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
    Liu LX; Chen WF; Xie JX; Wong MS
    Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinsonism produced by tetrahydroisoquinoline (TIQ) or the analogues.
    Yoshida M; Ogawa M; Suzuki K; Nagatsu T
    Adv Neurol; 1993; 60():207-11. PubMed ID: 8093578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
    Breidert T; Callebert J; Heneka MT; Landreth G; Launay JM; Hirsch EC
    J Neurochem; 2002 Aug; 82(3):615-24. PubMed ID: 12153485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct effects of intranigral L-DOPA infusion in the MPTP rat model of Parkinson's disease.
    Reksidler AB; Lima MM; Dombrowski PA; Barnabé GF; Andersen ML; Tufik S; Vital MA
    J Neural Transm Suppl; 2009; (73):259-68. PubMed ID: 20411784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective effect of riluzole in MPTP-treated mice.
    Araki T; Kumagai T; Tanaka K; Matsubara M; Kato H; Itoyama Y; Imai Y
    Brain Res; 2001 Nov; 918(1-2):176-81. PubMed ID: 11684056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions.
    Nagatsu T; Yoshida M
    Neurosci Lett; 1988 Apr; 87(1-2):178-82. PubMed ID: 2898112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enantio-specific induction of apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine.
    Maruyama W; Boulton AA; Davis BA; Dostert P; Naoi M
    J Neural Transm (Vienna); 2001; 108(1):11-24. PubMed ID: 11261742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-methyl-1,2,3,4-tetrahydroisoquinoline protects against rotenone-induced mortality and biochemical changes in rat brain.
    Antkiewicz-Michaluk L; Karolewicz B; Romańska I; Michaluk J; Bojarski AJ; Vetulani J
    Eur J Pharmacol; 2003 Apr; 466(3):263-9. PubMed ID: 12694809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.